Editorial: Advances in targeted therapy and biomarker research for endocrine-related cancers DOI Creative Commons

Yang Wu,

Zili Zhang

Frontiers in Endocrinology, Journal Year: 2024, Volume and Issue: 15

Published: Dec. 11, 2024

The field of endocrine-related cancers is undergoing rapid transformation, fueled by significant strides in deciphering the molecular and genetic foundations these diseases (1). These cancers, which encompass a range malignancies affecting endocrine system, present unique challenges due to their intricate interactions with hormonal signaling pathways (2). In recent years, surge development targeted therapies has sparked optimism for more precise personalized treatment options (3). Simultaneously, identification validation biomarkers have become crucial improving diagnosis, prognosis, decision-making, marking shift toward precision medicine. Moreover, cutting-edge research techniques, including organoid cultures organ-on-a-chip systems, emerged, providing accurate reliable models studying tumor biology drug responses (4). innovations highlight growing importance translational medicine, bridges gap between laboratory findings clinical applications, opening new understanding addressing cancers. This dynamic landscape calls comprehensive examination both current trends future directions complex diseases.The aim this Research Topic was accelerate pioneering deepen our By spotlighting groundbreaking studies on therapies, biomarker discovery, advanced modeling approaches like organoids platforms, we seek foster connection experimental practice. Our goal establish collaborative forum that not only disseminates scientific insights but also stimulates innovative therapeutic strategies, ultimately enhancing patient outcomes oncology. A series articles been published under Topic, as shown below.Head neck paragangliomas (HNPGNs) are infrequent tumors originate from parasympathetic paraganglia located at skull base (5). Standard options, surgery radiotherapy, carry considerable risks tumors' close proximity critical blood vessels cranial nerves (6). Diagnosing HNPGNs particularly challenging, distinguishing benign malignant forms cannot be solely achieved through histology or imaging (7). Gaining deeper microenvironment could unveil key markers associated growth malignancy, potentially enabling earlier detection, effective strategies prevent recurrences metastasis. Thyroid cancer originates thyroid gland, butterfly-shaped organ neck, its incidence rising years (10). Key risk factors include radiation exposure, mutations, family history, women being frequently affected (11). Treatment largely determined cancer's type stage, remove common approach.Remaining cells often treated radioactive iodine therapy (12). Given complexity disease need care, areas focus management.of research, latest advancements cancer. They identified several markers, BRAF RAS RET/PTC rearrangements, PAX8/PPARγ TERT promoter strongly disease. Understanding enables prognostication, tailored plans patients. Targeted treatments disrupt cells' mechanisms targeting specific molecules involved development. Among tyrosine kinase inhibitors, hormone receptor antagonists, therapy, immunotherapy, gene-targeted therapies. Further investigation focused discovering targets, tolerance, developing combination evolving provides hope effective, cancer.Liver hepatocellular carcinoma (LIHC) most prevalent primary liver third leading cause cancer-related deaths worldwide (13). It affects individuals chronic diseases, such those caused viral hepatitis, alcoholrelated damage, non-alcoholic fatty (14). Identifying biochemical can pinpoint high-risk groups timely intervention screening. Improving prevention efforts novel essential better outcomes. Yu et al. evaluated causal impact exposure factors, Alzheimer's disease, platelet count, ambidextrousness, cigarettes smoked per day, alcohol consumption, endocarditis, LIHC using two-sample MR study. Their provided compelling evidence supporting relationship reduced levels heightened vulnerability European population. Therefore, it recommended prioritize management lower counts minimize LIHC. As result, study contributes an expanding body literature indicating platelet-related agents holds promise potential approach early detection LIHC.In summary, collected provide focusing underpinnings tumors, presented offer into personalization. enhance guide precise, individualized approaches. aimed disrupting growth, represents promising avenue contribute shaping direction Lastly, thank all contributors who enriched submitting manuscripts highlighting highly valuable interesting studies.

Language: Английский

Self‐Accelerated Nanoregulators for Positive Feedback Ferroptosis‐Immunotherapy DOI Open Access
Xu Zhang, Xinlu Zhang, Qin Fan

et al.

Small, Journal Year: 2025, Volume and Issue: unknown

Published: March 3, 2025

Abstract Activating specific immunity through intelligent delivery of chemotherapeutic drugs shows great potential for effective tumor therapy. However, conventional microenvironment‐responsive nanomedicines are often difficult to achieve both specificity and sensitivity, leading severe adverse effects or limited drug release efficiency. Furthermore, the immunosuppressive microenvironment will also seriously restrict treatment efficacy. In this work, a cascade‐responsive multi‐polyprodrug nanoregulator is developed. Under with high hydrogen peroxide level, nanoregulators can simultaneously (doxorubicin), indoleamine 2,3‐dioxygenase 1 inhibitor (1‐methyl‐tryptophan) cinnamaldehyde in self‐accelerating manner. The combination reactive oxygen species‐induced ferroptosis doxorubicin‐induced apoptosis synergistically enhance immunogenic cell death activate immune response. released1‐methyl‐tryptophan promote cytotoxic T lymphocyte activation reduce escape by inhibiting tryptophan conversion. Meanwhile, it enhances species scavenging cystine/glutamate antiporter expression, achieving positive feedback ferroptosis‐immunotherapy. This work provides self‐accelerated strategy cooperation mode synergistic immunotherapy based on ferroptosis‐apoptosis.

Language: Английский

Citations

0
Membrane‐Anchoring and Oxygen‐Generating Mediated Nanosonosensitizer for Optimizing Cancer Immunotherapy DOI Open Access
Qing Zhao,

Ye ji Han,

Wushuang Gong

et al.

Advanced Healthcare Materials, Journal Year: 2025, Volume and Issue: unknown

Published: March 24, 2025

Despite its antitumor promise, sonodynamic therapy (SDT)'s efficacy in immune activation requires enhancement, primarily due to the hypoxic tumor microenvironment (TME) and insufficient targeting of sonosensitizers specific subcellular regions. Herein, we developed macrophage membrane (MM)-intermingled fusogenic liposomes (MFL) optimize sonoimmunotherapy that encapsulate catalase (CAT) within core incorporate sonosensitizer chlorin e6 (Ce6) outer shell (CAT@MM-MFL-Ce6). The MM confers evasion properties promotes nanoparticles' targeted accumulation tissue. fusion effect enables Ce6 anchor onto cancer cell facilitates direct delivery CAT into cytoplasm, bypassing endosomal degradation. Upon ultrasound stimulation, generated reactive oxygen species directly damage plasma membrane, initiating Caspase 3/Gasdermin E-mediated pyroptosis pathway. Concurrently, encapsulated efficiently decompose H₂O₂ thus enhancing local levels tumors. Contributed by these effects, combination nanosonosensitizer-augmented SDT checkpoint agent successfully reverse immunosuppressive TME, driving a potent response inhibits primary growth, distant metastasis, lung metastases an orthotopic triple-negative breast model. This study demonstrates potential novel SDT-based combinatorial approach modulate immune-cold TMEs, advancing proof-of-concept therapeutics.

Language: Английский

Citations

0
Fundamental knowledge and research regarding the role of immunity in triple-negative breast cancer from 2014–2024: A bibliometric analysis DOI Creative Commons
Xudong Li,

Chun Lou,

He Ren

et al.

Human Vaccines & Immunotherapeutics, Journal Year: 2025, Volume and Issue: 21(1)

Published: March 26, 2025

Immunity has vital research value and promising applications in triple-negative breast cancer (TNBC). Nevertheless, few bibliometric analyses have systematically investigated this area. This study aimed to comprehensively review the collaboration impact of countries, institutions, authors, journals on role immunity TNBC from a perspective, evaluate keyword co-occurrence knowledge structure, identify hot trends emerging topics. Articles reviews related were retrieved Web Science core collection using subject search. A was conducted primarily CiteSpace VOSviewer. total 3,104 articles included January 1, 2014, through December 31, 2024. The number immunization is rising. These publications are mainly 415 institutions 82 led by China USA. Among these publications, Lajos Pusztai published most papers, while Peter Schmid co-cited most. productive focused molecular biology, biological immunology, clinical medicine. Furthermore, co-citation analysis revealed that tumor microenvironment, biomarkers, immune checkpoint inhibitors current developing areas. keywords "immunotherapy" "nanoparticles" also likely be new focal points for future research. adopted visualization methods provide comprehensive TNBC. article will help researchers better understand dynamic evolution areas

Language: Английский

Citations

0
Nanosensitizer-assisted sonodynamic therapy for breast cancer DOI Creative Commons

Jing Yu,

Jun-Rui Hu,

Yi Tian

et al.

Journal of Nanobiotechnology, Journal Year: 2025, Volume and Issue: 23(1)

Published: April 7, 2025

Abstract Breast cancer is the most commonly diagnosed worldwide. Despite advancements in therapeutic modalities, its prognosis remains poor owing to complex clinical, pathological, and molecular characteristics. Sonodynamic therapy (SDT) a promising approach for tumor elimination, using sonosensitizers that preferentially accumulate tissues are activated by low-intensity ultrasound produce reactive oxygen species. However, clinical translation of SDT faces challenges, including limited efficiency resistance posed microenvironment. The emergence nanomedicine offers innovative strategies address these obstacles. This review discusses enhancing efficacy sonosensitizers, rational structural modifications, improved tumor-targeted enrichment, microenvironment remodeling, imaging-guided therapy. Additionally, SDT-based multimodal therapies, such as sono-chemotherapy, sono-immunotherapy, sono-photodynamic therapy, their potential applications breast treatment summarized. underlying mechanisms briefly outlined. Finally, this highlights current challenges prospects SDT, providing insights into future may improve outcomes cancer. Graphical abstract

Language: Английский

Citations

0
Recent Advances and Future Prospects in Biological-Membrane-Targeted Polymers DOI Creative Commons
Ran Chen, Yaping Liu, Yanan Jiang

et al.

Polymer science & technology., Journal Year: 2025, Volume and Issue: unknown

Published: April 30, 2025

Language: Английский

Citations

0
Editorial: Advances in targeted therapy and biomarker research for endocrine-related cancers DOI Creative Commons

Yang Wu,

Zili Zhang

Frontiers in Endocrinology, Journal Year: 2024, Volume and Issue: 15

Published: Dec. 11, 2024

The field of endocrine-related cancers is undergoing rapid transformation, fueled by significant strides in deciphering the molecular and genetic foundations these diseases (1). These cancers, which encompass a range malignancies affecting endocrine system, present unique challenges due to their intricate interactions with hormonal signaling pathways (2). In recent years, surge development targeted therapies has sparked optimism for more precise personalized treatment options (3). Simultaneously, identification validation biomarkers have become crucial improving diagnosis, prognosis, decision-making, marking shift toward precision medicine. Moreover, cutting-edge research techniques, including organoid cultures organ-on-a-chip systems, emerged, providing accurate reliable models studying tumor biology drug responses (4). innovations highlight growing importance translational medicine, bridges gap between laboratory findings clinical applications, opening new understanding addressing cancers. This dynamic landscape calls comprehensive examination both current trends future directions complex diseases.The aim this Research Topic was accelerate pioneering deepen our By spotlighting groundbreaking studies on therapies, biomarker discovery, advanced modeling approaches like organoids platforms, we seek foster connection experimental practice. Our goal establish collaborative forum that not only disseminates scientific insights but also stimulates innovative therapeutic strategies, ultimately enhancing patient outcomes oncology. A series articles been published under Topic, as shown below.Head neck paragangliomas (HNPGNs) are infrequent tumors originate from parasympathetic paraganglia located at skull base (5). Standard options, surgery radiotherapy, carry considerable risks tumors' close proximity critical blood vessels cranial nerves (6). Diagnosing HNPGNs particularly challenging, distinguishing benign malignant forms cannot be solely achieved through histology or imaging (7). Gaining deeper microenvironment could unveil key markers associated growth malignancy, potentially enabling earlier detection, effective strategies prevent recurrences metastasis. Thyroid cancer originates thyroid gland, butterfly-shaped organ neck, its incidence rising years (10). Key risk factors include radiation exposure, mutations, family history, women being frequently affected (11). Treatment largely determined cancer's type stage, remove common approach.Remaining cells often treated radioactive iodine therapy (12). Given complexity disease need care, areas focus management.of research, latest advancements cancer. They identified several markers, BRAF RAS RET/PTC rearrangements, PAX8/PPARγ TERT promoter strongly disease. Understanding enables prognostication, tailored plans patients. Targeted treatments disrupt cells' mechanisms targeting specific molecules involved development. Among tyrosine kinase inhibitors, hormone receptor antagonists, therapy, immunotherapy, gene-targeted therapies. Further investigation focused discovering targets, tolerance, developing combination evolving provides hope effective, cancer.Liver hepatocellular carcinoma (LIHC) most prevalent primary liver third leading cause cancer-related deaths worldwide (13). It affects individuals chronic diseases, such those caused viral hepatitis, alcoholrelated damage, non-alcoholic fatty (14). Identifying biochemical can pinpoint high-risk groups timely intervention screening. Improving prevention efforts novel essential better outcomes. Yu et al. evaluated causal impact exposure factors, Alzheimer's disease, platelet count, ambidextrousness, cigarettes smoked per day, alcohol consumption, endocarditis, LIHC using two-sample MR study. Their provided compelling evidence supporting relationship reduced levels heightened vulnerability European population. Therefore, it recommended prioritize management lower counts minimize LIHC. As result, study contributes an expanding body literature indicating platelet-related agents holds promise potential approach early detection LIHC.In summary, collected provide focusing underpinnings tumors, presented offer into personalization. enhance guide precise, individualized approaches. aimed disrupting growth, represents promising avenue contribute shaping direction Lastly, thank all contributors who enriched submitting manuscripts highlighting highly valuable interesting studies.

Language: Английский

Citations

1